Tyra Biosciences (TYRA) Cash & Equivalents (2020 - 2026)
Quarterly Cash & Equivalents fell 15.65% to $85.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $85.0 million through Mar 2026, down 15.65% year-over-year, with the annual reading at $77.4 million for FY2025, 15.85% down from the prior year.
Tyra Biosciences filings provide 7 years of Cash & Equivalents readings, the most recent being $85.0 million for Q1 2026.
- Cash & Equivalents hit $85.0 million in Q1 2026 for Tyra Biosciences, up from $77.4 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $292.5 million in Q1 2022 and bottomed at $58.0 million in Q4 2023.
- Average Cash & Equivalents over 5 years is $164.9 million, with a median of $103.9 million recorded in 2024.
- The largest annual shift saw Cash & Equivalents skyrocketed 107.98% in 2022 before it crashed 76.91% in 2023.
- Tyra Biosciences' Cash & Equivalents stood at $251.2 million in 2022, then crashed by 76.91% to $58.0 million in 2023, then skyrocketed by 58.55% to $92.0 million in 2024, then fell by 15.85% to $77.4 million in 2025, then rose by 9.78% to $85.0 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Cash & Equivalents are $85.0 million (Q1 2026), $77.4 million (Q4 2025), and $62.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 901.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 2.96 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 18.44 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | 84.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.96 Mn |
| Dec 31, 2025 | 77.39 Mn |
| Sep 30, 2025 | 61.95 Mn |
| Jun 30, 2025 | 98.49 Mn |
| Mar 31, 2025 | 100.72 Mn |
| Dec 31, 2024 | 91.97 Mn |
| Sep 30, 2024 | 103.89 Mn |
| Jun 30, 2024 | 99.49 Mn |
| Mar 31, 2024 | 254.37 Mn |
| Dec 31, 2023 | 58.01 Mn |
| Sep 30, 2023 | 215.65 Mn |
| Jun 30, 2023 | 232.41 Mn |
| Mar 31, 2023 | 241.70 Mn |
| Dec 31, 2022 | 251.21 Mn |
| Sep 30, 2022 | 263.21 Mn |
| Jun 30, 2022 | 275.11 Mn |
| Mar 31, 2022 | 292.50 Mn |
| Dec 31, 2021 | 302.18 Mn |
| Sep 30, 2021 | 312.82 Mn |
| Jun 30, 2021 | 135.20 Mn |
| Mar 31, 2021 | 140.64 Mn |
| Dec 31, 2020 | 15.22 Mn |
| Sep 30, 2020 | 18.07 Mn |